Key result
Deletion of PDGFRβ in a mouse model of diabetic MASH significantly attenuated hepatic inflammation and fibrosis at 12 weeks and reduced liver tumorigenesis at 20 weeks.
Why the study?
PDGF contributes to steatohepatitis progression, but changes in and characteristics of isoform-specific expression remain unclear in diabetic metabolic dysfunction-associated steatohepatitis.
Does deletion of PDGFRβ suppress tumorigenesis and steatohepatitis progression in a mouse model of diabetic MASH?
Does deletion of PDGFRβ suppress tumorigenesis and steatohepatitis progression in a mouse model of diabetic MASH?
Deletion of PDGFRβ suppresses the progression of steatohepatitis and tumorigenesis in a diabetic MASH mouse model, potentially through modulation of miRNA expression.
PDGFRβ deletion attenuates diabetic MASH progression in mice; hypothesis-generating for targeted inhibition, with human translation untested.
The platelet-derived growth factor (PDGF) family contributes to the progression of steatohepatitis; however, changes in and the characteristics of isoform-specific expression remain unclear. Since diabetes is a major driver of metabolic dysfunction-associated steatohepatitis (MASH), we characterized the mouse model of diabetic MASH (dMASH) by focusing on PDGF signaling. Pdgfa-d expression was markedly higher in hepatic stellate cells among flow-sorted cells in control mice and also increased in dMASH. In contrast, a reanalysis of human single-cell RNA-Seq data showed the distinct distribution of each PDGF isoform with disease progression. Furthermore, inflammation and fibrosis in the liver were less severe in diabetic MASH using tamoxifen-induced PDGF receptor β (PDGFRβ)-deficient mice (KO) than in control dMASH using floxed mice (FL) at 12 weeks old. Despite the absence of tumors, the expression of tumor-related genes was lower in KO than in FL. Tumorigenesis was significantly lower in 20-week-old KO. An Ingenuity Pathway Analysis of differentially expressed miRNA between FL and KO identified functional networks associated with hepatotoxicity and cancer. Therefore, PDGFRβ signals play important roles in the progression of steatohepatitis and tumorigenesis in MASH, with the modulation of miRNA expression posited as a potential underlying mechanism.
No takes yet. Share an insight, caveat, or question.
Wada et al. (2024) studied Diabetic metabolic dysfunction-associated steatohepatitis (dMASH). PDGFRβ deletion vs. Floxed control mice (FL) was evaluated on Tumorigenesis and progression of steatohepatitis. Deletion of PDGFRβ in a mouse model of diabetic MASH significantly attenuated hepatic inflammation and fibrosis at 12 weeks and reduced liver tumorigenesis at 20 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: